Astec LifeSciences Q2 FY27: loss widens 53% YoY to ₹37.4 Cr as margins compress

Astec LifeSciences' consolidated loss widened to ₹37.40 Cr in Q2 FY27 (quarter ended September 2026), from ₹24.42 Cr a year ago — a roughly 53% deepening of losses even as revenue from operations was nearly flat YoY at ₹72.02 Cr (-2.3%). Quarter-on-quarter, revenue fell 13.8% from ₹83.56 Cr and the loss nearly doubled from ₹18.71 Cr, but agrochemicals demand is seasonal and the sequential dip shouldn't be read as fresh deterioration — the YoY comparison is the more meaningful one, and it shows the loss getting worse, not better. Standalone figures track consolidated closely (loss ₹37.43 Cr, EPS -₹16.80 vs consolidated -₹16.79), so there's no material divergence between the two bases. The widening loss is a margin story, not a revenue story. Operating margin collapsed to -27.48% from -9.07% a year ago and -0.80% last quarter, and net margin widened to -51.93% from -32.63% YoY. Finance costs were the single biggest swing factor, up 33% YoY and 45% QoQ to ₹11.18 Cr, on borrowings of ₹330.50 Cr at quarter-end — down from ₹448.93 Cr at FY26-end, but still heavy enough to outweigh a roughly flat cost base elsewhere (material and employee costs were both marginally lower YoY). Notably, the P&L weakness masks a strong cash quarter: consolidated operating cash flow for H1 FY27 came in at ₹121.96 Cr (versus an outflow of ₹19.95 Cr in H1 FY26), almost entirely from a ₹139.80 Cr collection in trade receivables (down to ₹107.91 Cr from ₹247.72 Cr at FY26-end). That cash funded a roughly ₹118 Cr cut in total borrowings over the half, but also left the period-end cash balance at just ₹0.15 Cr against ₹10.05 Cr at FY26-end — a balance sheet now leaner on both debt and cash. No analyst consensus or brokerage preview for this specific quarter could be found despite searching, so vsStreet is unknown; our records and the filing carry no formal management guidance either, so there is no guidance bar to grade this print against. No exceptional items hit the current or year-ago quarter — the Rs.209.43 lakh labour-code exceptional charge noted in the filing sits entirely in FY26 full-year numbers — so the YoY comparison above is already like-for-like. The quarter's other disclosed developments (closure of the trading window ahead of results, and three separate exchange queries on stock-volume surges between September and October) were administrative/compliance matters unrelated to operating performance; no management press release accompanied this filing to independently frame the results.